Inpart, the platform purpose-built for biopharma partnering and external innovation.

Trusted by 500+ organizations across the life sciences ecosystem, including 70% of the world’s top 50 pharmaceutical companies. Inpart helps life science teams discover and evaluate external innovation more effectively.

Through a global scientific discovery network spanning 3,000+ research institutions and 6,000+ emerging biotech companies, they proactively surface new partnering opportunities aligned with our clients’ scientific priorities.

Inpart’s AI-enabled platform then supports the full partnering lifecycle; helping BD, R&D, Alliance Management and leadership teams structure evaluation workflows, collaborate across teams, and capture critical decision insights. By transforming fragmented evaluation data into structured intelligence, organizations gain better visibility across their external pipeline and unlock the foundation for AI-driven insight.

Deal is Inpart’s industry-leading partnering intelligence platform that helps BD, R&D, Alliance Management and leadership teams structure the evaluation and management of external opportunities across the partnering life-cycle. The platform captures scientific and commercial evaluation data, enables efficient collaboration across teams, and creates a clear history of partnering evaluations and decisions.

By transforming fragmented opportunity data into structured intelligence, Deal unlocks AI-driven insights that help organizations surface patterns across evaluations, identify strategic gaps, and generate portfolio-level visibility, enabling leadership teams to answer critical partnering questions in minutes and make faster, more reliable decisions.